232
Views
7
CrossRef citations to date
0
Altmetric
Art

Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET

, &
Pages 505-508 | Received 22 Jul 2009, Accepted 23 Nov 2009, Published online: 12 May 2010

References

  • Molitch ME. Prolactin in human reproduction. In: Strauss III JF, Robert LB, editors. Yan and Jaffe's reproductive endocrinology; physiology pathophysiology, and clinical management. 5th ed. Philadephia, PA; 2004. p 93–123.
  • Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003;2:23–32.
  • Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. Clin Endocrinol Metab 1984;59:941–948.
  • McNeilly AS, Glasier A, Jonassen J, Howie PW. Evidence for direct inhibition of ovarian function by prolactin. J Reprod Fertil 1982;65:559–569.
  • Nawroth F. Hyperprolactinaemia and the regular menstrual cycle in asymptomatic women: should it be treated during therapy for infertility? Reprod Biomed Online 2005;11:581–588.
  • Reinthaller A, Deutinger J, Csaicsich P, Riss P, Müller-Tyl E, Fischl F, Janisch H. [Effect of serum prolactin on cycle stimulation and fertilization of human oocytes]. Geburtshilfe Frauenheilkd. 1987;47:246–248.
  • Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006;125:152–164.
  • Zollner U, Lanig K, Steck T, Dietl J. Assessment of endocrine status in patients undergoing in-vitro fertilization treatment. Is it necessary? Arch Gynecol Obstet 2001;265:16–20.
  • Laufer MR, Floor AE, Parsons KE, Kuntz KM, Barbieri RL, Friedman AJ. Evaluation of hormonal testing in the screening for in vitro fertilization (IVF) of women with tubal factor infertility. J Assist Reprod Genet 1995;12:93–96.
  • Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14:228–238.
  • Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995;49:255–279.
  • Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, et al Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.
  • Doldi N, Papaleo E, De Santis L, Ferrari A. Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs. Gynecol Endocrinol 2000;14:437–441.
  • Jinno M, Katsumata Y, Hoshiai T, Nakamura Y, Matsumoto K, Yoshimura Y. A therapeutic role of prolactin supplementation in ovarian stimulation for in vitro fertilization: the bromocriptine-rebound method. J Clin Endocrinol Metab 1997;82:3603–3611.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.